Exploiting natural killer cells for therapy of melanoma;Die nutzung natürlicher killerzellen für die therapie des melanoms

JDDG - Journal of the German Society of Dermatology

Volumn 13, Issue 1, 2015, Pages 23-29

  Hölsken, Oliver ^a   Miller, Matthias ^a   Cerwenka, Adelheid ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D;

ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELL THERAPY; EFFECTOR CELL; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; MELANOMA CELL; NATURAL KILLER CELL; PROTEIN EXPRESSION; REVIEW; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84920774335     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12557     Document Type: Review

References (33)

1. Pflugfelder A, Kochs C, Blum A et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges 2013; 11 Suppl 6: 1-116, 1-26.
2. Cummins DL, Cummins JM, Pantle H et al. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81: 500-7.
3. Raaijmakers MI, Rozati S, Goldinger SM et al. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy 2013; 5: 169-82.
4. Kageshita T, Wang Z, Calorini L et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993; 53: 3349-54.
5. Vivier E, Tomasello E, Baratin M et al. Functions of natural killer cells. Nat Immunol 2008; 9: 503-10.
6. Lakshmikanth T, Burke S, Ali TH et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119: 1251-63.
7. Pietra G, Manzini C, Rivara S et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72: 1407-15.
8. Schlecker E, Fiegler N, Arnold A et al. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res 2014; 74: 3429-40.
9. Paschen A, Sucker A, Hill B et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15: 5208-15.
10. Baginska J, Viry E, Berchem G et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A 2013; 110: 17450-5.
11. Kono K, Salazar-Onfray F, Petersson M et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26: 1308-13.
12. Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatol Ges 2014; 12(11): 1021-7.
13. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172: 7335-40.
14. Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 2013; 6: 135-46.
15. Fregni G, Messaoudene M, Fourmentraux-Neves E et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 2013; 8: e76928.
16. McKay K, Moore PC, Smoller BR, Hiatt KM. Association between natural killer cells and regression in melanocytic lesions. Hum Pathol 2011; 42: 1960-4.
17. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Current advances and perspectives in the treatment of advanced melanoma. J Dtsch Dermatol Ges 2012; 10: 319-25.
18. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
19. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
20. Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105: 2594-600.
21. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
22. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17: 6287-97.
23. Tam YK, Martinson JA, Doligosa K, Klingemann HG. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003; 5: 259-72.
24. Arai S, Meagher R, Swearingen M et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10: 625-32.
25. Vey N, Bourhis JH, Boissel N et al. A phase 1 trial of the antiinhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317-23.
26. Ni J, Miller M, Stojanovic A et al. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012; 209: 2351-65.
27. Romee R, Schneider SE, Leong JW et al. Cytokine activation induces human memory-like NK cells. Blood 2012; 120: 4751-60.
28. Braumuller H, Wieder T, Brenner E et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494: 361-5.
29. Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009; 15: 2123-9.
30. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447: 482-6.
31. Paolino M, Choidas A, Wallner S et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 2014; 507: 508-12.
32. Chan CJ, Martinet L, Gilfillan S et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15: 431-8.
33. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-92.